Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay

Topic: Disease mechanisms in lab and animal studies

Frontotemporal dementia (FTD) is the most common neurodegenerative disorder in individuals under age 60 and has no treatment or cure. Because many cases of FTD result from GRN nonsense mutations, an animal model for this type of mutation is highly desirable for understanding pathogenesis and testing therapies. Here, we generated and characterized Grn R493X knockin mice, which model the most common human GRN mutation, a premature stop codon at arginine 493 (R493X). Homozygous Grn R493X mice have markedly reduced Grn mRNA levels, lack detectable progranulin protein, and phenocopy Grn knockout mice, with CNS microgliosis, cytoplasmic TDP-43 accumulation, reduced synaptic density, lipofuscinosis, hyperinflammatory macrophages, excessive grooming behavior, and reduced survival. Inhibition of nonsense-mediated mRNA decay (NMD) by genetic, pharmacological, or antisense oligonucleotide-based approaches showed that NMD contributes to the reduced mRNA levels in Grn R493X mice and cell lines and in fibroblasts from patients containing the GRN R493X mutation. Moreover, the expressed truncated R493X mutant protein was functional in several assays in progranulin-deficient cells. Together, these findings establish a murine model for in vivo testing of NMD inhibition or other therapies as potential approaches for treating progranulin deficiency caused by the R493X mutation.

Key findings

• Because many cases of FTD result from GRN nonsense mutations, an animal model for this type of mutation is highly desirable for understanding pathogenesis and testing therapies.
• Inhibition of nonsense-mediated mRNA decay (NMD) by genetic, pharmacological, or antisense oligonucleotide-based approaches showed that NMD contributes to the reduced mRNA levels in Grn R493X mice and cell lines and in fibroblasts from patients containing the GRN R493X mutation.
• Together, these findings establish a murine model for in vivo testing of NMD inhibition or other therapies as potential approaches for treating progranulin deficiency caused by the R493X mutation.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1073/pnas.1722344115
• PubMed: 29511098
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{nguyen2018-29511098,
  author  = {Nguyen, A. D. and Nguyen, T. A. and Zhang, J. and Devireddy, S. and Zhou, P. and Karydas, A. M. and Xu, X. and Miller, B. L. and others},
  title   = {{Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay}},
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  year    = {2018},
  doi     = {10.1073/pnas.1722344115},
  pmid    = {29511098},
  url     = {https://doi.org/10.1073/pnas.1722344115}
}

Related studies in Drug development

• Progranulin deficiency promotes neuroinflammation through cathepsin B-mediated activation of the NLRP3 inflammasome bioRxiv · 2026-10-13 · usefulness score 16/100
• Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer’s Disease and Type 2 Diabetes Frontiers in Aging Neuroscience · 2021-12-16 · usefulness score 43/100
• Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model Protein & cell · 2021-07-21 · usefulness score 43/100
• Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer's disease Aging · 2019-01-01 · usefulness score 41/100
• Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model Frontiers in psychiatry · 2011-10-21 · usefulness score 40/100
• mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease Research Square · 2025-09-16 · usefulness score 16/100

Similar studies

• Selective vulnerability and resilience of thalamic neuronal populations in Frontotemporal Dementia 2026 · Lewy body dementia
• Frontotemporal Dementia Patient Neurons With Progranulin Deficiency Display Protein Dyshomeostasis 2023 · Disease mechanisms
• Impaired protein degradation in FTLD and related disorders 2016 · Disease mechanisms
• Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease 2015 · Genetics
• Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis 2017 · Brain scans and imaging
• TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy 2019 · Brain tissue and pathology

More on Drug development

• A review that covers this ground Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019-10 · usefulness score 39/100
• Newest in this subject The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration Metabolism: clinical and experimental · 2026-10-30 · Peer-reviewed · usefulness score 45/100
• Newest in this subject Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Drug development →